

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

(Securities code: 4597)

March 30, 2018

To Our Shareholders:

Yoshihiro Arai,
President and Chief Executive Officer
Solasia Pharma K.K.
4F, SUMITOMO FUDOSAN SHIBA-
KOEN TOWER, 2-11-1, Shiba-koen,
Minato-ku, Tokyo

Notice of the Resolutions Adopted at the 10th Annual General Meeting of Shareholders

Solasia Pharma K.K. (the “Company”) is pleased to inform you that the matters noted below were reported and resolved at the 10th Annual General Meeting of Shareholders held on March 30, 2018.

Reported Item The Business Report, the Consolidated Financial Statements and the Non-Consolidated Financial Statements for the 10th fiscal year (from January 1, 2017 to December 31, 2017), and the results of audits of the Consolidated Financial Statements by the Independent Auditor and the Audit & Supervisory Board.

This item was reported at the meeting accordingly.

Resolved Items

Proposal No. 1: Election of Six Board Directors
This was approved and resolved as originally proposed. Six (6) directors, namely, Yoshihiro Arai, Toshio Miyashita, Masahiro Michisuji, Stanley Lau, Norikazu Eiki, and Tajio Enoki were elected; and all assumed their offices.

Proposal No. 2: Election of One Audit & Supervisory Board Member
This was approved and resolved as originally proposed. Jiro Fujiyama was elected as replacement of Tasuku Toita who resigned at the conclusion of the Meeting; and he assumed his office. As provided for the Articles of Incorporation of the Company, the term of office of the Audit & Supervisory Board Member elected to fill a vacancy corresponds to the remaining term of office of his predecessor.

-END-